{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:35:16Z","timestamp":1793036116672,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T00:00:00Z","timestamp":1279065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The efficacy and safety of zanolimumab (HuMax\u2010CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty\u2010one adult patients with relapsed or refractory CD4<jats:sup>+<\/jats:sup> PTCL of non\u2010cutaneous type (angioimmunoblastic T cell lymphoma (AITL) <jats:italic>n<\/jats:italic>\u2003=\u20039, PTCL\u2010not otherwise specified (NOS) <jats:italic>n<\/jats:italic>\u2003=\u20037, anaplastic large cell lymphoma (ALCL) <jats:italic>n<\/jats:italic>\u2003=\u20034 and enteropathy type T cell lymphoma <jats:italic>n<\/jats:italic>\u2003=\u20031) were treated in a single\u2010arm multi\u2010centre study, with weekly intravenous infusions of zanolimumab 980\u2003mg for 12\u2003weeks. Median age was 69\u2003years (range 26\u201385). Seventeen of the patients had advanced stage disease (Ann Arbor stages III\u2013IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252\u2003d. Responses were obtained in different PTCL entities: AITL (<jats:italic>n<\/jats:italic>\u2003=\u20033), ALCL (<jats:italic>n<\/jats:italic>\u2003=\u20031) and PTCL\u2010NOS (<jats:italic>n<\/jats:italic>\u2003=\u20031). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980\u2003mg weekly demonstrated clinical activity and an acceptable safety profile in this poor\u2010prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08298.x","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T15:30:21Z","timestamp":1279121421000},"page":"565-573","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Phase II trial of zanolimumab (HuMax\u2010CD4) in relapsed or refractory non\u2010cutaneous peripheral T cell lymphoma"],"prefix":"10.1111","volume":"150","author":[{"given":"Francesco","family":"D\u2019Amore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20107"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057673"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:2S:S27"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90281-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0796-845"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"e_1_2_8_17_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_8_19_1","volume-title":"World Health Organization Classification of Tumours: Patholgy and Genetics of Tumours of Haematopietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1309\/HEFL7KC435KFWEX8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062877"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138800"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V77.1.20.20","article-title":"Observations on the effect of chimeric anti\u2010CD4 monoclonal antibody in patients with mycosis fungoides","volume":"77","author":"Knox S.J.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T\u2010cell lymphoma with chimeric anti\u2010CD4 monoclonal antibody","volume":"87","author":"Knox S.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.V89.3.980","article-title":"Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T\u2010 and null\u2010cell type and Hodgkin\u2019s disease: evidence for distinct cellular origin","volume":"89","author":"Krenacs L.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.49.2.154"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European\u2010American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non\u2010Hodgkin\u2019s lymphoma","volume":"89","author":"Melnyk A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20531"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476910802129661"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_35_1","first-page":"62","article-title":"Immunohistological markers for the diagnosis of cutaneous lymphomas","volume":"8","author":"Ralfkiaer E.","year":"1991","journal-title":"Seminars in Diagnostic Pathology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1148"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190210183"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0176-2"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1215"},{"key":"e_1_2_8_42_1","first-page":"171","article-title":"Retrospective analysis of 23 cases with peripheral T\u2010cell lymphoma, unspecified: clinical characteristics and outcome","volume":"82","author":"Zaja F.","year":"1997","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08298.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08298.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:45:48Z","timestamp":1697453148000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08298.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08298.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08298.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,18]]},"assertion":[{"value":"2010-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}